pharmaphorum August 29, 2024
Digital therapeutics (DTx) developer Curio has raised over $10 million in first-round financing that will be used to fund the rollout of its MamaLift Plus app for postpartum depression (PPD).
The DTx, which was approved by the FDA in April under the 510(k) regulatory route used for software as a medical device (SaMD) products, is an eight-week neurobehavioral intervention that can be prescribed for women aged 22 years and older with mild to moderate PPD as an adjunct to clinician‐managed outpatient care.
The Series A was backed by UK healthcare investor RYSE Asset Management – which set up a dedicated $50 million fund for digital health projects earlier this year – alongside Otsuka subsidiary ONCE, Bridge Point Capital and Avestria.
...Today's Sponsors
Today's Sponsor